Obio Technology (Shanghai) Valuation

Q: What is the Fair Price of 688238 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688238 (CN¥5.48) is trading below our estimate of [[fair value]] (CN¥16.14)

Is 688238 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688238 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688238 (CN¥5.48) is trading below our estimate of fair value (CN¥16.14)

Significantly Below Fair Value: 688238 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688238?

Key metric: As 688238 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688238. This is calculated by dividing 688238's market cap by their current revenue.
What is 688238's PS Ratio?
PS Ratio	14.1x
Sales	CN¥251.68m
Market Cap	CN¥3.71b

688238 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.9x
Enterprise Value/EBITDA	-17.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688238's PS Ratio compare to its peers?

The above table shows the PS ratio for 688238 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.4x
301230 PharmaResources (Shanghai)	6.8x	20.9%	CN¥3.6b
688202 Shanghai Medicilon	4.9x	51.6%	CN¥5.0b
300813 Zhejiang Tailin BioEngineeringLtd	7.3x	n/a	CN¥2.3b
688315 Novogene	2.6x	17.5%	CN¥5.4b
688238 Obio Technology (Shanghai)	14.1x	22.8%	CN¥3.7b

Price-To-Sales vs Peers: 688238 is expensive based on its Price-To-Sales Ratio (14.1x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does 688238's PS Ratio compare vs other companies in the CN Life Sciences Industry?

0 Companies	Price / Sales	Estimated Growth	Market Cap

No more companies available in this PS range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688238 is expensive based on its Price-To-Sales Ratio (14.1x) compared to the CN Life Sciences industry average (5.1x).

Price to Sales Ratio vs Fair Ratio

What is 688238's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688238 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.1x
Fair PS Ratio	2.8x

Price-To-Sales vs Fair Ratio: 688238 is expensive based on its Price-To-Sales Ratio (14.1x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥51.8b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.19

1.8%

12.2%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.87

-5.5%

11.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

-0.4%

15.5%